AU564648B2 - Insulin agent - Google Patents

Insulin agent

Info

Publication number
AU564648B2
AU564648B2 AU30917/84A AU3091784A AU564648B2 AU 564648 B2 AU564648 B2 AU 564648B2 AU 30917/84 A AU30917/84 A AU 30917/84A AU 3091784 A AU3091784 A AU 3091784A AU 564648 B2 AU564648 B2 AU 564648B2
Authority
AU
Australia
Prior art keywords
denotes
insulin
phe
formula
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30917/84A
Other languages
English (en)
Other versions
AU3091784A (en
Inventor
Ulrich Grau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU3091784A publication Critical patent/AU3091784A/en
Application granted granted Critical
Publication of AU564648B2 publication Critical patent/AU564648B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/625—Extraction from natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU30917/84A 1983-07-22 1984-07-20 Insulin agent Ceased AU564648B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3326473 1983-07-22
DE19833326473 DE3326473A1 (de) 1983-07-22 1983-07-22 Pharmazeutisches mittel zur behandlung des diabetes mellitus

Publications (2)

Publication Number Publication Date
AU3091784A AU3091784A (en) 1985-01-24
AU564648B2 true AU564648B2 (en) 1987-08-20

Family

ID=6204661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30917/84A Ceased AU564648B2 (en) 1983-07-22 1984-07-20 Insulin agent

Country Status (19)

Country Link
US (1) US4608364A (enExample)
EP (1) EP0132769B1 (enExample)
JP (1) JPS6042334A (enExample)
AT (1) ATE31625T1 (enExample)
AU (1) AU564648B2 (enExample)
CA (1) CA1236012A (enExample)
DE (2) DE3326473A1 (enExample)
DK (1) DK172456B1 (enExample)
ES (1) ES8504456A1 (enExample)
FI (1) FI79786C (enExample)
GR (1) GR81550B (enExample)
HU (1) HUT34889A (enExample)
IE (1) IE57690B1 (enExample)
IL (1) IL72468A (enExample)
NO (1) NO167187C (enExample)
NZ (1) NZ208960A (enExample)
PH (1) PH21328A (enExample)
PT (1) PT78941A (enExample)
ZA (1) ZA845621B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DE3880346T2 (de) * 1987-02-25 1993-07-29 Novonordisk As Insulinderivate.
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US6875589B1 (en) 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE58906966D1 (de) * 1988-06-23 1994-03-24 Hoechst Ag Mini-Proinsulin, seine Herstellung und Verwendung.
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
WO1992010284A2 (en) 1990-12-07 1992-06-25 Cnc Development, Inc. Catalytic chemical reactor
YU66892A (sh) * 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
TW224471B (enExample) * 1991-11-26 1994-06-01 Lilly Co Eli
EP0545198B1 (de) * 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptide mit insulinartiger Wirkung
CA2087087C (en) * 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521004A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. INSULIN RECEPTOR PART AGONISTS
WO2025068976A1 (en) 2023-09-28 2025-04-03 Biotts Inc. Compositions comprising insulin agonists, and said compositions for use in the treatment of diabetes or obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650679A5 (de) * 1981-08-27 1985-08-15 Lilly Co Eli Gegen diabetes mellitus wirksames pharmazeutisches mittel.
CH650677A5 (de) * 1981-08-27 1985-08-15 Lilly Co Eli Gegen diabetes mellitus wirksames pharmazeutisches mittel.
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
CH650680A5 (de) * 1981-08-27 1985-08-15 Lilly Co Eli Pharmazeutisches mittel aus human-insulin, human-c-peptid und human-proinsulin.
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.

Also Published As

Publication number Publication date
US4608364A (en) 1986-08-26
FI842915A0 (fi) 1984-07-19
IL72468A (en) 1989-08-15
IE841890L (en) 1985-01-22
FI79786B (fi) 1989-11-30
JPH0469128B2 (enExample) 1992-11-05
PT78941A (de) 1984-08-01
AU3091784A (en) 1985-01-24
JPS6042334A (ja) 1985-03-06
EP0132769B1 (de) 1988-01-07
NO167187C (no) 1991-10-16
EP0132769A1 (de) 1985-02-13
GR81550B (enExample) 1984-12-11
DK172456B1 (da) 1998-08-24
HUT34889A (en) 1985-05-28
FI79786C (fi) 1990-03-12
DE3326473A1 (de) 1985-01-31
DK358384D0 (da) 1984-07-20
DK358384A (da) 1985-01-23
CA1236012A (en) 1988-05-03
DE3468323D1 (en) 1988-02-11
ES534488A0 (es) 1985-05-01
IL72468A0 (en) 1984-11-30
FI842915L (fi) 1985-01-23
ES8504456A1 (es) 1985-05-01
NZ208960A (en) 1989-02-24
NO842978L (no) 1985-01-23
PH21328A (en) 1987-10-13
NO167187B (no) 1991-07-08
ATE31625T1 (de) 1988-01-15
IE57690B1 (en) 1993-03-10
ZA845621B (en) 1985-02-27

Similar Documents

Publication Publication Date Title
AU3091784A (en) Insulin agent
ES8505646A1 (es) Procedimiento para la preparacion de un derivado de insulina
HU9400350D0 (en) Retard peptides
EP0464022A4 (en) Insulinotropic hormone
DE69025336D1 (de) Antihypertensive Zubereitungen und deren Verwendung
NZ208831A (en) Imidazolium derivatives and pharmaceutical compositions
HUT38950A (en) Process for producing 2-substituted-1,3-propylidene-diphosphonate derivatives and pharmaceutical compositions containing them as active agents
ZA894508B (en) Pharmaceutical compounds
AU572612B2 (en) Isoxazole derivatives
JPS5344616A (en) Injections
PH27520A (en) Sulphonamides containing a tetrazolyl radical
AU542310B2 (en) Glicentin related purified peptide having 30 amino acids
JPS53119067A (en) Electric color emitting display body
ZA828877B (en) Therapeutically useful 3,7a-diazacyclohepta(j,k)fluorene derivatives
ZA902167B (en) Thienylpiperazines,process for the preparation thereof,the use thereof,and pharmaceuticals containing these and the preparation thereof
IL111361A0 (en) Pharmaceutical compositions for the treatment of insulin dependent diabetes mellitus (iddm)
MX9709958A (es) Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired